Fundraising Fox
/Companies
Sign in

Iktos

Paris, FR · 3 known investors

Find your way into Iktos

Sign up to find every way you can get introduced to Iktos

  • Your email: who you already know at Iktos, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Iktos team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials. It serves chemists and drug discovery teams seeking to accelerate research through rapid, customizable synthesis planning.

AI & Machine LearningBiotechDeep TechMedical Devices

Founders & leadership

Y
YannCo-founder and CEO
Q
QuentinCo-founder and CSO
N
NicolasCo-founder and CTO

Investors · 3

Debiopharm Innovation FundreportedLausanne · $1M – $5M

How we know: funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

Omnes CapitalreportedParis

How we know: prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 4

Altos LabsAltos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
ACTOActo provides a mobile app platform for field-based sales teams in regulated industries to deliver training, coaching, and presentations with approved content and messaging. The solution includes keyword search, knowledge tracking via surveys, and push notification alerts for content updates.
PathosPathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
MytosMytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.

Companies working in the same space as Iktos.

In the news

Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutionsprnewswire.com · Mar 2023

Frequently asked questions

What does Iktos do?
Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials. It serves chemists and drug discovery teams seeking to accelerate research through rapid, customizable synthesis planning.
Who founded Iktos?
Iktos was founded by Yann, Quentin, Nicolas.
Who are Iktos's investors?
Iktos's investors include M Ventures, Debiopharm Innovation Fund, Omnes Capital.
Where is Iktos headquartered?
Iktos is headquartered in Paris, FR.